Clinical importance of B7-H3 expression in human pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Clinical importance of B7-H3 expression in human pancreatic cancer.

Clinical importance of B7-H3 expression in human pancreatic cancer.

http://www.wikidata.org/entity/Q37424100

about

From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Molecular mechanism underlying lymphatic metastasis in pancreatic cancer PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations B7-H3 overexpression in pancreatic cancer promotes tumor progression.B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients.The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer.B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome B7-h3 and its role in antitumor immunity B7-H3 expression in breast cancer and upregulation of VEGF through gene silence Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma.Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c.B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells.Pancreatic ductal adenocarcinoma: a review of immunologic aspects.Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma.Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response.B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma.B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer Correlation between B7-H3 expression and matrix metalloproteinases 2 expression in pancreatic cancer Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer.B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer.Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer.Structure and T cell inhibition properties of B7 family member, B7-H3.MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.B7-H3-mediated tumor immunology: Friend or foe?Strategies to relieve immunosuppression in pancreatic cancer.The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence.Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes.Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells.

P2860

Q26765123-B7955749-C70C-4F53-8E9B-83A4C947988F Q26999345-E3E604E8-CEC4-4FAE-9840-C36E042011F1 Q28075712-5563B064-2318-4D0E-87F5-C72070756B4A Q33703916-D3EEFD4B-0EAE-49BA-BEEC-53EF486AB9E9 Q33967711-81BA4F4D-CE7B-4833-BFC5-050EBD628665 Q34093668-01A1821B-14C2-4202-AFBB-6473FA7983AD Q34105913-26A09A20-D6D0-436E-9ED0-B8675EB11C34 Q34356712-0AFD02D7-3EC4-45F1-9909-641918B629F7 Q34446315-C5B261C2-1A0D-4EEA-9DF3-A40A8A8BBACA Q34538321-E7611E9D-41D0-4147-AB55-8644B4343F44 Q34577158-C53E89AF-EACB-4E4C-B641-20A96423208C Q34935785-71A4ECBF-66B4-4DFD-BB88-EF2C36D303EA Q35032331-E044C6CE-F29F-4D1D-ABD3-6D99C05232EA Q35104159-19DCD4D8-5972-489B-9A9F-D8B719133A74 Q35660790-F27EF38A-A67E-40F5-824B-DF35B4CB3DA4 Q35867721-B2AB08DB-087D-41F8-B3BA-481D30F8C18F Q35870682-535947A0-DB7B-4A82-AA81-CCC8BDC1E2EF Q35871253-F6FEF5F9-FBAC-4B19-8477-59A6AE1339EB Q35886496-19EC8DA3-A19B-4A71-AEE3-558FBD498921 Q36207260-0E8AC682-CB76-47A1-BD62-7A8BF4B7D8CF Q36429035-302D9306-711A-49E5-B2ED-C00CDFD8AF0F Q36444198-9B256CEA-404C-4073-AC2A-B7334A60DBA4 Q36621122-EED51CC3-2157-428D-AF6E-72AFB4357E85 Q36640287-46FFE0A0-B06C-481E-A4E4-0AE2A4658D0D Q37116249-35260092-A3FE-4451-8CF3-6937BA981CFA Q37269305-0077A3E2-B87D-4370-93C9-BB5DD200A71C Q37301864-5D173761-6298-4F18-9AA4-B6CFC7907415 Q37362510-52418CB4-E66B-425E-82CA-7B233650505F Q37697212-4E53CDFE-61ED-4172-AC1B-6279D22E5546 Q37721055-E575648C-80F2-457F-B570-3463F84AB156 Q38040302-68066BE1-1B52-4802-8B10-573F3D9C0F01 Q38135281-4851930C-CE8C-44F8-80D3-B31DA6326702 Q38445328-3F8D4906-AD15-43DB-88C8-052CB32E07E2 Q38684886-062B2910-5539-4D49-87C3-160DC4913DD5 Q39160982-EAD17D5F-DD14-4310-84F4-E194C63832A6 Q39163764-F351E24D-5736-4BFC-96C5-B5DAC39F3CCD Q39325949-0F750EA0-5790-4ED1-A013-A9A3AEA66205 Q39446788-9E8860F4-C004-4D00-8607-743C5DF6FD33 Q39524901-D4F7B48F-1D38-4689-9A7E-3FE6A7C857F7 Q42728633-8945EE97-A431-4029-A1C2-503F51E226E9

P2860

Clinical importance of B7-H3 expression in human pancreatic cancer.

http://www.wikidata.org/entity/Q37424100

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical importance of B7-H3 expression in human pancreatic cancer.

@en

Clinical importance of B7-H3 expression in human pancreatic cancer.

@nl

type

label

Clinical importance of B7-H3 expression in human pancreatic cancer.

@en

Clinical importance of B7-H3 expression in human pancreatic cancer.

@nl

prefLabel

Clinical importance of B7-H3 expression in human pancreatic cancer.

@en

Clinical importance of B7-H3 expression in human pancreatic cancer.

@nl

P1433

Q37424100-8301F0DC-7F6A-4650-AB70-0F1B7452CD98

P1476

Q37424100-1779817E-6A23-4409-8C91-9DB88BE77E85

P2093

Q37424100-17714D25-6F89-48FE-A940-31C309633834

Q37424100-1D2D0DF1-EAAC-4F14-AA99-A9520A8A8A44

Q37424100-235FC1DE-2182-4226-ABF1-C0498FF70EFD

Q37424100-26999785-DB5B-4EEB-AF17-3AE67D1A2124

Q37424100-4C1EC4AA-1704-47A4-BE3C-4FA6506594F9

Q37424100-4C6D49C5-CF70-4486-8D63-DF4247C35186

Q37424100-6F164880-38DD-4734-8566-2FA2CBF8B507

Q37424100-7FDE9C71-160B-45C6-8697-AD8C223BAEA9

Q37424100-858BCA6D-0FB6-437C-BE65-96D891780104

Q37424100-9A30421F-1927-4B46-8CEE-1BDE290D6AF4

P2860

Q37424100-00D60953-B097-4F29-A2EF-85729AAE69C6

Q37424100-084A8110-CB31-43AE-B1C2-518A621370E5

Q37424100-0AD84078-F528-4781-B018-44094CCE2596

Q37424100-0AED8270-D81B-4E41-985D-F90BC068D0CD

Q37424100-13BFD74B-D1C6-49B8-B515-674DDD5F24D8

Q37424100-160E6EF5-13D2-46BA-AF39-FF569FF705DB

Q37424100-2E32768B-65DD-4A7B-89BC-F145C59CB236

Q37424100-3C0800EA-0979-46C6-93D6-027E0070CB8F

Q37424100-3D05E322-D055-4A21-BDFB-4B0099EE64E5

Q37424100-3D0AC103-9EE9-4967-B2A4-8EF2D3F02F69

P2888

Q37424100-FE7A06B5-C11B-4657-828E-2DDEA690FA38

P304

Q37424100-BCF61327-D84E-421C-8B60-058254A867BE

P31

Q37424100-D586E0FC-70FD-4C2B-8E10-515345AC475F

P356

Q37424100-838769AF-5F0A-4ABB-A4C1-F919F91667AC

P407

Q37424100-5781C12A-6A4B-434B-8297-451927349878

P433

Q37424100-7BB0C57E-1E1C-435B-AD19-4914D0969D30

P478

Q37424100-F0C7E899-2FC8-4D8C-8D9D-BA28BC4E2EC2

P577

Q37424100-2070B74C-76AE-4883-92B1-5CFC8750C33F

P5875

Q37424100-2AB53D36-71F1-47E6-906A-09C94A0FA5F9

P6179

Q37424100-2505B991-7A61-442D-9A7F-8A6129075122

P698

Q37424100-E93E84C3-8114-4E69-B67A-631CAADAC4B7

P932

Q37424100-BF4158E5-2BE9-41E0-A7B5-A159D2230C99

P356

P1433

British Journal of Cancer

P1476

Clinical importance of B7-H3 expression in human pancreatic cancer.

@en

P2093

H Kanehiro

http://www.w3.org/2001/XMLSchema#string

H Yagita

http://www.w3.org/2001/XMLSchema#string

I Yamato

http://www.w3.org/2001/XMLSchema#string

K Hotta

http://www.w3.org/2001/XMLSchema#string

K Shimada

http://www.w3.org/2001/XMLSchema#string

M Sho

http://www.w3.org/2001/XMLSchema#string

N Konishi

http://www.w3.org/2001/XMLSchema#string

T Akahori

http://www.w3.org/2001/XMLSchema#string

T Nomi

http://www.w3.org/2001/XMLSchema#string

Y Nakajima

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

Characterization of mouse and human B7-H3 genes

The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses

Cancer statistics, 2007

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Pancreatic cancer

P2888

P304

1709-1716

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605375

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38025198

http://www.w3.org/2001/XMLSchema#string

P6179

1018571095

http://www.w3.org/2001/XMLSchema#string

P698

19844235

http://www.w3.org/2001/XMLSchema#string

P932

2778545

http://www.w3.org/2001/XMLSchema#string